Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

Ultragenyx Pharmaceutical Inc. ( RARE ) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A September 17, 2026 5:30 PM EDT Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Eric Crombez - Chief Medical Officer & Executive VP Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Steven Ionov - TD Cowen, Research Division Maurice Raycroft - Jefferies LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Lydia Erdman - Goldman Sachs Group, Inc., Research Division Tejas Wein - Barclays Bank PLC, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Maxwell Skor - Morgan Stanley, Research Division Laura Chico - Wedbush Securities Inc., Research Division Presentation Operator Good afternoon, and welcome to the Ultragenyx Pharmaceutical conference call to discuss the U.S. Food and Drug Administration approval of the FAYUVI for the treatment of the MPS IIIA, also known as Sanfilippo Syndrome Type A. [Operator Instructions] It is now my pleasure to turn the call over to Joshua Higa, Chief of Staff and Vice President of Investor Relations. Please go ahead. Joshua Higa Director of Investor Relations & Corporate Communications [indiscernible] the U.S. FDA approval of FAYUVI, the first-ever treatment for Sanfilippo syndrome Type A. We appreciate all of you making time to join us this afternoon to discuss this important milestone. A press release with details on this announcement is available on our website, along with an updated corporate presentation. Joining me today are Emil Kakkis, Chief Executive Officer and President; Eric Crombez, Chief Medical Officer; and Erik Harris, Chief Commercial Officer. Howard Horn, Chief Financial Officer, is also on the line for Q&A.